New resource provides complete and practical information for prostate
cancer patients and their families
MONTREAL, June 5, 2012 /CNW Telbec/ - "You have prostate cancer" are
four words that can instantly change a man's life. Future plans and
next steps may seem insurmountable as the newly diagnosed patient wades
through information that may be complicated or inaccurate. A new
resource, authored by two renowned urologists and researchers, Dr. Fred
Saad and Dr. Michael McCormack, and funded by Sanofi Canada, may help
allay fears and answer questions. Prostate Cancer: Understand the disease and its treatment is a simple, complete and practical guide geared at helping patients and
their families understand prostate cancer and may be an indispensable
resource for the some 26 5001 Canadian men affected by this disease.
"This book is one of the rare works to give so much attention to the
psychological impact of a prostate cancer diagnosis on the patient and
those close to him," says Dr. Saad, professor of surgery at the
University of Montreal, chief of Urology and Director of Urologic
Oncology at the University of Montreal Hospital Centre (Centre Hospitalier de l'Université de Montréal, CHUM). "As prostate cancer touches a very sensitive place in the male
psyche, we wanted to pay special attention to this information."
"We are extremely pleased with the book," says Dr. McCormack assistant
head of urology at the University of Montreal Hospital Centre (Centre Hospitalier de l'Université de Montréal, CHUM) and associate clinical professor in the Department of Surgery, Faculty
of Medicine, University of Montreal. "Not only were we able to address
common questions, we also discussed the role of diet and nutritional
supplements in the prevention of prostate cancer, making this book a
valuable resource for men at an increased risk of developing the
disease. We are grateful to Sanofi Canada for their support."
Information is key for patients
In Canada, one man in seven men will develop prostate cancer. It is the
most frequently diagnosed cancer in men and its incidence has increased
by 30 percent since 1988. While it is most commonly diagnosed after age
70, prostate cancer can also occur in men in their forties and fifties.2
"Information is key to patient well-being and comfort," says Malvina
Klag, Executive Director at PROCURE, Quebec's prostate cancer charity.
"We continue to need coordinated resources for men diagnosed with
prostate cancer. Awareness, education and information are critical to
help combat this distressingly common disease. This book hits all the
A rewarding contribution
Sanofi Canada along with Dr. Fred Saad and Dr. Michael McCormack, helped
to produce this significant resource.
"At Sanofi, we are committed to patients and understand the importance
of giving them tools and resources to help better manage their
disease," says Victoria Vertesi, Senior Director, Oncology Patient
Centered Unit, Sanofi Canada. "Sanofi is focused on answering patients'
unmet needs and supporting innovative solutions. Partnering with
experts such as Drs. Saad and McCormack is an example of our dedication
and leadership in this area."
Illustrated in colour, this third edition of Prostate Cancer has become an indispensable reference work. This edition explains how a
man can maintain his virility and continue to lead an active and
enjoyable life and shows that mortality rates are dropping thanks to
better treatments, even though the incidence of the disease is on the
Ordering Prostate Cancer - Understand the disease and its treatment
Prostate Cancer can be purchased in bookstores and online bookstores (as
a hard copy or electronic book). For a complimentary hardcopy, please
contact, PROCURE at 1-866-899-CURE or by email at email@example.com.
Sanofi, a global and diversified healthcare leader, discovers, develops
and distributes therapeutic solutions focused on patients' needs.
Sanofi has core strengths in the field of healthcare with seven growth
platforms: diabetes solutions, human vaccines, innovative drugs,
consumer healthcare, emerging markets, animal health and the new
Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York
Sanofi companies in Canada include sanofi-aventis Canada Inc.
(pharmaceuticals), Sanofi Pasteur (vaccines), Sanofi Consumer Health
(health and beauty), Genzyme (rare diseases) and Merial (animal
health). Together they employ more than 1,700 people, mainly in the
greater Montreal and Toronto areas. In 2011 Sanofi companies invested
$151.7 million in R&D in Canada, creating jobs, business and
opportunity throughout the country.
Annika Parance Publishing
From the "Understand the Disease and Its Treatment" collection
2012 - 206 pages - 18,95 $
Photos and colour illustrations
5 3/8 x 8 3/8 inches
Also available in French
About the authors
Dr. Fred Saad is a professor of surgery at the University of Montreal. He is
currently chief of Urology and Director of Urologic Oncology at the
University of Montreal Hospital Centre (Centre Hospitalier de l'Université de Montréal, CHUM). He also heads the Molecular Prostate Cancer Research Lab at the
Montreal Cancer Institute and is Director of Oncology Research at the
CHUM research centre.
Since 2004, he has held the University of Montreal Chair in Prostate
Research. In 2005, he received the Leadership Award in Medicine from the
University of Montreal Hospital Centre. He is currently coordinating
more than 40 clinical and basic research projects in urologic oncology.
Dr. Michael McCormack is a urologist, the assistant head of urology at the University of
Montreal Hospital Centre (Centre Hospitalier de l'Université de Montréal, CHUM) and associate clinical professor in the Department of Surgery, Faculty
of Medicine, University of Montreal. He served as chair of the Quebec
College of Physicians' Urology Examination Committee and vice-chair of
the Examination Board in urology at the Royal College of Physicians and
Surgeons of Canada.
Dr. McCormack is also the author of Male Sexual Health (Rogers, 2003). In 2010, he was awarded a Prix Esculape in recognition of the
excellence of his teaching at the University of Montreal Hospital
SOURCE Sanofi Canada
For further information: